Caltech researchers have developed BrainCAB, a small-molecule delivery system designed to help medicines cross the blood-brain barrier. The technology modifies brinzolamide, a glaucoma drug, to bind to a receptor on brain blood vessels and transport therapeutic cargo into the brain. Tested in rodents and nonhuman primates, BrainCAB increased delivery of an antibody-based cancer treatment. The preclinical platform could potentially support delivery of antibodies, proteins and RNA medicines, though human trials are still required.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.